



August 10, 2018

**BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip code: 512529 **The National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip code: SEQUENT

Dear Sir/ Madam,

## Subject: Unaudited financial results for the quarter ended June 30, 2018 (Revised)

This is with reference to the intimation submitted by the Company on the captioned subject on August 9, 2018, kindly note that on account of typographical issue, we are submitting herewith revised Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2018.

The change is on account of the following:

"Point No 7 under Notes to the Statement of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2018:

- Revenue from operation was erroneously mentioned as INR 128.30 Lakhs instead of INR 1283.01 Lakhs.
- The amount of Loss After Tax relating to Bremer was erroneously mentioned as INR 4.53 Lakhs instead of INR 45.29 Lakhs."

You are requested to take the same on record.

Thanking you,

Yours faithfully, For Sequent Scientific Limited

Krupesh Mehta Company Secretary

Encl: A/a

## SeQuent Scientific Limited

# Deloitte Haskins & Sells

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru – 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

# INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

 We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2018 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3. The Statement includes the results of the following entities:
  - Alivira Animal Health Australia Pty Ltd;
  - ii) Alivira Animal Health Limited, Ireland;
  - iii) Alivira Animal Health Limited, India;
  - iv) Alivira Saude Animal Brasil Participacoes Ltda;
  - v) Alivira UA Limited;
  - vi) Alivira France
  - vii) Bremer Pharma GMBH;
  - viii) Comercial Vila Veterinaria de Lleida S.L;
  - ix) Elysian Life Sciences Private Limited;
  - x) Fendigo BV;
  - xi) Fendigo SA;
  - xii) Interchange Veterinária Indústria E Comércio Ltda;
  - xiii) Laboratorios Karizoo, S.A;
  - xiv) Laboratorios Karizoo, S.A. De C.V. (Mexico);
  - xv) N-Vet AB;
  - xvi) Phytotherapic Solutions S.L;
  - xvii) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
  - xviii) SeQuent Antibiotics Private Limited;

# Deloitte Haskins & Sells

- xix) SeQuent Pharmaceuticals Private Limited;
- xx) SeQuent Research Limited;
- xxi) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;
- xxii) Vila Viña Participacions S.L;
- 4. Based on our review conducted as stated above and based on the consideration of the review reports of other auditors referred to in paragraph 5 below, and except for the possible effects of the matters described in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. We did not review the interim financial results of twelve subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.16,443.46 lakhs for the quarter ended June 30, 2018, and total profit after tax of Rs.534.79 lakhs and total comprehensive income of Rs.534.79 lakhs for the quarter ended June 30, 2018, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

6. The consolidated unaudited financial results includes the interim financial results of nine subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue Rs.434.72 lakhs for the quarter ended June 30, 2018, and total loss after tax of Rs.806.15 lakhs and total comprehensive loss of Rs.802.15 lakhs for the quarter ended June 30, 2018, as considered in the consolidated unaudited financial results.

For **DELOITTE HASKINS & SELLS** Chartered Accountants (Firm's Registration No. 008072S)

Sathya P. Koushik Partner (Membership No. 206920)

Mumbai, August 9, 2018 SPK/JKS/2018

# Sequent

Proven Ability in Life Scient

### SEQUENT SCIENTIFIC LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

iii or come     181.00     391.00     392.20     1068.10       iii Total hormen (HV)     22.244.00     392.77     197.255.00     197.255.00       iiii Total hormen (HV)     22.244.00     22.214.20     197.255.00     197.255.00       iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	L	STATEMENT OF CONSOLIDATED UNAODITE				(Rs. in Lakhs)	
Image: Control operations (http://dxi.org/1000000000000000000000000000000000000		Particulars		ended	months ended in the previous year		
1         Social State			UNAUDITED		UNAUDITED	AUDITED	
11010.0020.100020.100020.100020.100020.1000171810.000010.000010.000010.000010.000010.000010.00001810.000010.000010.000010.000010.000010.000010.000010.00001810.000010.000010.000010.000010.000010.000010.000010.00001910.000010.000010.000010.000010.000010.000010.000010.00001910.000010.000010.000010.000010.000010.000010.000010.00001010.000010.000010.000010.000010.000010.000010.000010.00001010.000010.000010.000010.000010.000010.000010.000010.00001010.000010.000010.000010.000010.000010.000010.000010.000010.00001010.0000	h	Revenue from operations ( Refer note 5)	23,515.20		19,423.20	84,944.80	
V         Expense         No.         No.         No.         No.           V         (C. d. anternation constrained (C. D. Participate of tables) insigned (C. d. Participate of tables) in	11	These de Altre Altre de Ch	181.40	291.86	362.30	1,658.10	
scale         105.07.00         10		Total Income (I+II)	23,696.60	23,567.72	19,785.50	86,602.90	
scale         105.07.00         10							
a)b)A) <td></td> <td></td> <td></td> <td>10 700 00</td> <td>7.040.40</td> <td>04.450.40</td>				10 700 00	7.040.40	04.450.40	
c)         (1)			CALVE THE AVE				
in the second		which have not been as the assessment of the second s	as the strength	all and a second	and the second se	more and	
i0.2.0.00002.2.0.00002.2.0.00000.0.0.00001.1.0.2.00000.7.0.00000000000000000000000000000000			(1,211.20)	(1,590.06)	Construction of the second	ACA (5-03-062-220)	
in Prace cents         1776.20         087.00         01.023         03.0800           is Dependent on isomistants reportes         55.06         04.000         55.05         44.04.00         145.05           is Dependent on isomistants reportes         50.000         55.05         44.04.00         145.05           is Dependent on isomistants reportes         50.000         55.05         44.04.00         15.05           isomistant reportes         50.000         55.05         44.04.00         25.04.00           isomistant reportes         60.00         55.05         44.04.00         25.04.00           isomistant reportes         60.00         50.05         15.00         15.00           isomistant reportes         60.00         50.05         15.00         15.00           isomistant reportes         60.00         25.00         25.00         15.00           isomistant reportes         10.00         25.00         25.00         15.00         25.00           isomistant reportes         10.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00         25.00			-	-	The sub-sub-	Perfect Second	
Bit Proceediation with a minimization sequence         Bits 20 (0): Other sequence         Bits 20 (2): 0: 0: 0: 0: 0: 0: 0: 0: 0: 0: 0: 0: 0:			Sec. N	and a state of the state of the	Validation March	and the second s	
No. 000000000000000000000000000000000000		Contract Con	377 CA 679 721	La conserva sa	2019/06/02/22	0.6210 /0212 / 1	
Image:				and the second second second			
v         profilessing from continuing operations before tax (no.)         660.00         1,49.1,77         22.91.42           V         profilessing from continuing operations before tax (N-V)         660.00         150.42         -         150.42           V         profilessing from continuing operations before tax (N-V)         660.00         660.00         150.42         -         150.42           V         profilessing from continuing operations before tax (N-V)         660.00         660.00         150.42         22.92.30         119.86.00           (N) ACT cast estimation of tax         360.72         52.82         22.92.30         119.86.00         10.00           (N) ACT cast estimation of the site of th							
V         Exceptional lateral local (galar) (not) (rode rotes ii)         1150.40         1150.40         1150.40           VM         Proteit[locas] from continuing operations before tax (V-VI)         600.50         1,250.77         233.87         233.84           VM         Reservations         320.07         62.58         223.30         1150.40           (a) Content list         (A) Treats entitiened         (B) AV Treats entitiened its         (B) AV Treats entitiened operations after tax (VI-VIII)         (A40.00         (A40.00 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
v         refut(ses) from centimular generations heffore tax (V-V)         600.00         1,260.77         2,86.47           VM         Rar sequence         0         0.200.00 <td< td=""><td></td><td></td><td></td><td>and the second</td><td>251.07</td><td>041.001</td></td<>				and the second	251.07	041.001	
Vin         Tax separate         Unit         Tax separate         Unit         Unit <thunit< th="">         Unit         <thunit< th=""> <thunit< th="">         Unit<td>VI</td><td>Exceptional items loss/ (gain) (net) (Refer note 6)</td><td></td><td>150.40</td><td></td><td>150.40</td></thunit<></thunit<></thunit<>	VI	Exceptional items loss/ (gain) (net) (Refer note 6)		150.40		150.40	
Normal tax         340.70         25.23         223.30         1198.00           Normal tax         (8.46)         (3.58)         -         6.99           (9.) Mart credit entitienent witten off         .         228.70         .         228.70           (9.) Mart credit entitienent witten off         .         228.70         .         228.70           (13.00)         71.80         . <td>VI</td> <td>Profit/(loss) from continuing operations before tax (V-VI)</td> <td>690.90</td> <td>1,250.77</td> <td>251.07</td> <td>2,364.48</td>	VI	Profit/(loss) from continuing operations before tax (V-VI)	690.90	1,250.77	251.07	2,364.48	
Not Control extistment         (0,400)         (-)         (0,500)           (c) MAT cost extistment witten off         (-)         (-)         (0,500)           Test Lar expense (MI)         (-)         (-)         (0,500)           (c) Material exceptions         (-)         (-)         (0,500)           (c) Material exceptions         (-)         (-)         (-)         (-)           (c) Material exceptions         (-)         (-)         (-)         (-)           (c) Material exceptions         (-)         (-)         (-)         (-)         (-)           (c) Material exceptions         (-)         (	VII	I Tax expense					
i         0.047 codd entilisers division of intervent within of intervent withintervent within of intervent withintervent within of in		<ul> <li>Per a construction of the second secon</li></ul>		101010000000	223.30	1,196.80	
Image: space			(84.80)	(3.90)		(3.90)	
Table ax expenses (VIII)         242.50         447.55         112.60         1,445.70           IX         Profit(loss) from continued operations Care on object as asstitutibilities introductible to the discontinued operations Care on object as asstitutibilities introductible to the discontinued operations Trac expenses of discontinued operations after tax. (Vii-VIII)         - <td></td> <td>(c) MAT credit entitlement written off</td> <td></td> <td>286.70</td> <td></td> <td>286.70</td>		(c) MAT credit entitlement written off		286.70		286.70	
ID         Profit/joss/from continuing operations after tax (VI-VIII)         448.09         843.24         58.47         1,1018.76           X         Profit/joss/from discontinued operations fax operate of discontinued operations (a).Current tax         -         -         -         -         41,004.50           (a).Current tax         Gian on disposal of assertimed to filabilities antibutable to the discontinued operations fax operate of discontinued operations after tax (Refer note 4)         - </td <td></td> <td>(d).Deferred tax</td> <td>(13.00)</td> <td>71.80</td> <td>(30.70)</td> <td>(133.90)</td>		(d).Deferred tax	(13.00)	71.80	(30.70)	(133.90)	
X         Profit/joss/from discontinued operations crac cepters of discontinued operations frac cepters of discontinued operations (a) Current tax         -		Total tax expenses (VIII)	242.90	407.53	192.60	1,345.70	
Amon on disposal of assortized element of italiabilities attributable to the discontinued operations         39,284,00         -         41,005,00           Yac expense of discontinued operations         -         -         382,273         -         382,273           (b). MAT readit entitienent         -         39,284,00         -         382,273         166,33         42,064,20           XI         Profit(Joss) for the period (X+X)         448,00         40,489,97         224,70         43,882,88           XI         Profit(Joss) for the period (X+X)         448,00         40,489,97         224,70         43,882,88           XI         Profit(Joss) for disord thereins fains         (5,00)         92,41         (8,60)         82,50           (a) Ro-massurement gain(Joss) from investment is nearly instruments         (7,711,80)         (5,090,01)         (3,220,80)         (14,195,41)           (a) Exchange differences on translator of forign operations         (13,65,5)         162,16         (66,10)         224,66         (2,62,01,70)         (14,195,41)           Yat cherres on net investment in foreign operations         (13,65,5)         162,16         (6,6,10)         (2,82,01,70)         (2,92,170)         (2,92,170)         (2,92,170)         (2,92,170)         (2,92,171,12)         (3,82,16,10)         (13,84,16,16)         (	IX	Profit/(loss) from continuing operations after tax (VII-VIII)	448.00	843.24	58.47	1,018.78	
(a). Current tax         -         (b). MAT croatel attiluanted.         -         (b). MAT croate attiluanted.         (b). Current tax         (c). Current tax	x	Gain on disposal of assets/settlement of liabilities attributable to the discontinued operations		39,264.00	10120203/0000	<b>1,054.70</b> 41,009.50	
(b)         MAT credit entilement         (362.73)         (362.73)           Profit(loss) from discontinued operations after tax. (Refer note 4)         336,82.73         166.23         42,064.20           XI         Profit(loss) form discontinued operations after tax. (Refer note 4)         444.00         40,469.37         224.70         43,062.38           XI         Other comprehensive income Items that will not be reclassified to profit or loss         (6.00)         62.241         (6.60)         62.251           (a).Re-measurement quint(has) on defined benefits plans         (6.00)         62.241         (6.60)         26.261           (a).Re-measurement quint(has) on defined benefits plans         (7.711.90)         (5.090.01)         (3.200.00)         (14.195.44)           (a).Exchange differences on tradiation of foruign operations         (7.817.95)         162.16         (66.10)         244.66           (b).Exchange differences on the intervelime in foreign operations         (7.837.95)         (4.855.90)         (2.977.00)         223.211.42           Total comprehensive income         (7.407.95)         35.94.47         223.70         42.765.59           Viet comparishes income for the period XI-XIII         (7.045.95)         35.964.87         223.70         42.765.59           Viet comprehensive income for the period attributable to:         12.00		President All Presentation				260.72	
Profiv(loss) from discontinued operations after tax (Refer note 4)         38,528.73         1662.23         42,064.20           XI         Profiv(loss) for the period (X+X)         448.00         40,489.57         224.70         43,082.98           XII         Other comprehensive income         -         -         -         -           Isome that will not be reclassified to profit or loss         (5.00)         92.41         (3.60)         82.50           (a) Re-measurement qui/(usp) from investment in equivy instruments         (7.711.90)         (5.098.07)         (3.230.80)         (14.195.41)           (a) Re-measurement qui/(usp) from investment in equivy instruments         (7.711.90)         (5.098.07)         (3.230.80)         (14.195.41)           (a) Exchange differences on trainstation of foreign operations         (35.551         228.54         98.60         (3.61)           (a) Exchange differences on trainstation of foreign operations         (35.551         228.54         98.60         (3.61)           Total other comprehensive income for the period (X+XII)         (7.949.85)         34,964.87         223.70         42,165.58           VII         Total comprehensive income for the period XIributable to:         -         -         -         -           - Owners of the Company         (7.434.55)         (4.585.60)         <		The light has the second distance of the seco		(362.73)			
XII         Other comprehensive income terms that will not be reclassified to profit or loss (a) Re-measurement gain/(oss) on defined benefits plans (b).Fair value gain / (dos) for investment in equity instruments (c) (5.00)         (5.00)         (5.2.11)         (3.60)         (5.2.50)           (a) Re-measurement gain/(oss) on defined benefits plans (b).Ear value gain / (dos) for investment in equity instruments (c) (D).Ear value gain / (dos) for investment in equity instruments (c) (D).Ear value gain / (dos) for investment in equity instruments (c) (D).Ear value gain / (dos) for investment in foreign operations (c) (D).Ear value for mergen size in come (c) (D).Ear value comprehensive income for the period attributable to: - owners of the Company - Non-controlling interests (c) Comers of the Company - No		Product of Constant State St		Parts Granter		42,064.20	
Items that will not be reclassified to profit or loss         (5.00)         92.41         (3.60)         82.50           (9), Re-measurement gain(0:s0) on defined benefits plans         (5.00)         92.41         (3.60)         82.20           (9), Re-measurement gain(0:s0) on defined benefits plans         (7.711.90)         (5.090, 00)         (3.23.00)         (14.195.41)           (10), Exit value gain (0:s3) from investment in oreign operations         (135.55)         182.16         (66.10)         244.65           (0), Exit value gain (0:s3) from investment in foreign operations         (135.55)         182.85.44         98.300         (3.271.00)         (13.871.86           (0), Exchange differences on netinvestment in foreign operations         (3.280, 00)         35.914.07         (2.977.00)         29.211.12           Value form prohensive income for the period (XI+XII)         (7.049.95)         35.914.07         (2.977.00)         29.211.12           Profit for the period attributable to:         -         -         -         -         223.70         42.155.85           - Non-controlling interests         (7.493.45)         (4.580.50)         (3.280, 00)         (13.984.86)           - Non-controlling interests         (7.105.45)         35.366.37         (3.045.30)         28.20.172           - Non-controlling interests	XI	Profit/(loss) for the period (IX+X)	448.00	40,469.97	224.70	43,082.98	
Items that will not be reclassified to profit or loss         (5.00)         92.41         (3.60)         82.50           (9), Re-measurement gain(0:s0) on defined benefits plans         (5.00)         92.41         (3.60)         82.20           (9), Re-measurement gain(0:s0) on defined benefits plans         (7.711.90)         (5.090, 00)         (3.23.00)         (14.195.41)           (10), Exit value gain (0:s3) from investment in oreign operations         (135.55)         182.16         (66.10)         244.65           (0), Exit value gain (0:s3) from investment in foreign operations         (135.55)         182.85.44         98.300         (3.271.00)         (13.871.86           (0), Exchange differences on netinvestment in foreign operations         (3.280, 00)         35.914.07         (2.977.00)         29.211.12           Value form prohensive income for the period (XI+XII)         (7.049.95)         35.914.07         (2.977.00)         29.211.12           Profit for the period attributable to:         -         -         -         -         223.70         42.155.85           - Non-controlling interests         (7.493.45)         (4.580.50)         (3.280, 00)         (13.984.86)           - Non-controlling interests         (7.105.45)         35.366.37         (3.045.30)         28.20.172           - Non-controlling interests	X	Other comprehensive income					
(a).Re-measurement gain/(loss) on defined benefits plans         (5.00)         92.41         (3.60)         82.50           (b).Fair value gain / (loss) from investment in quily instruments         (7.711.90)         (5.099.01)         (3.230.80)         (14.155.41)           terms that may be reclassified to profit or loss         (136.56)         162.16         (66.10)         2244.56           (a).Exchange differences on tensitation of foreign operations         (136.55)         162.16         (66.10)         2244.56           (b).Exchange differences on tensitation of foreign operations         (136.55)         162.16         (66.10)         224.11.22           Total other comprehensive income         (7.471.90)         32.914.07         (2.977.00)         29.211.12           Profit for the period attributable to:							
(b).Fair value gain / (bos) from investment in equity instruments         (7,711.90)         (5,099.01)         (3,230.80)         (14,195.41           terms that may be reclassified to profit or loss         (355.55)         162.16         (66.10)         244.56           (a).Exchange differences on nel investment in foreign operations         (355.55)         128.54         98.80         (3.61)           Total other comprehensive income         (7,497.95)         (4,555.90)         (3,20.70)         (13,871.86)           XIII         Total comprehensive income for the period (XI+XII)         (7,049.95)         33,954.47         (2,977.00)         229,211.12           Profit for the period attributable to:         -		Transfer The second sec	(5.00)	92.41	(3.60)	82.50	
Items that may be reclassified to profit or loss         .         .           (a), Exchange differences on transition of foreign operations         (136,56)         162.16         (66,10)         244.56           (b), Exchange differences on net investment in foreign operations         3555.51         288.54         98.80         (3,617,65)           Total other comprehensive income for the period (XI+XII)         (7,497.95)         (4,565,50)         (2,297.00)         29,211.12           VIII         Total comprehensive income for the period (XI+XII)         (7,049.85)         33,954.87         223.70         42,155.58           • Non-controlling interests         120.00         515.10         1.00         926.40           • Owners of the Company         (7,433.45)         (4,585.50)         (3,295.00)         (13,954.86           • Non-controlling interests         120.00         515.10         1.00         926.40           • Owners of the Company         (7,433.45)         (4,585.50)         (3,295.00)         (13,954.86           • Non-controlling interests         (84.50)         32.60         32.90         67.30         83.00           Total comprehensive income for the period attributable to:			a second as	-11-25,017 -	and the second se		
(a).Exchange differences on translation of foreign operations         (136.56)         162.16         (66.10)         244.66           (b).Exchange differences on net investment in foreign operations         355.51         288.54         68.80         (3.61)           Total other comprehensive income         (7,497.95)         (4,555.90)         (3,201.70)         (13,871.86           XIII         Total comprehensive income for the period (XI+XII)         (7,049.95)         35,914.07         (2,977.00)         25,211.12           Profit for the period attributable to:         -         -         -         -         42,165.58           - Non-controlling interests         120.00         515.10         1.00         928.40           - Owners of the Company         (7,433.45)         (4,588.50)         (3,269.00)         (13,954.86           - Non-controlling interests         (64.50)         32.60         32.60.30         83.00           - Owners of the Company         (7,155.45)         35.366.37         (3,045.30)         28.20.172           - Non-controlling interests         55.50         547.70         68.30         1,009.40           - Owners of the Company         (7,155.45)         35.366.37         (3,045.30)         28.20.172           - Non-controlling interests         55.50			() · · · · · · ·	V-1			
(b). Exchange differences on net investment in foreign operations         355.51         288.54         98.80         (3.51)           Total other comprehensive income         (7,497,95)         (4,555.90)         (3,201.70)         (13,871,86)           XIII         Total comprehensive income for the period (XI+XII)         (7,049,93)         35,914.07         (2,977.00)         29,211,12           Profit for the period attributable to:         -         -         -         -         223.70         42,155.58           - Owners of the Company         328.00         39,954.87         223.70         42,155.58           - Non-controlling interests         120.00         515.10         1.00         926.40           Other comprehensive income for the period attributable to:         -         -         -         -           - Owners of the Company         (7,433.45)         (4,585.50)         (3,265.00)         (13,954.86           - Owners of the Company         (7,105.45)         35,366.37         (3,045.30)         228,201.72           - Owners of the Company         (7,105.45)         35,366.37         (3,045.30)         228,201.72           - Owners of the Company         (7,105.45)         35,366.37         (3,045.30)         228,201.72           - For continuing operations         -<			(136,56)	162.16	(66.10)	244.66	
Total other comprehensive income         (7,497.95)         (4,555.90)         (3,201.70)         (13,871.86           XIII         Total comprehensive income for the period (XI+XII)         (7,049.95)         35,914.07         (2,977.00)         29,211.12           Profit for the period attributable to: -Owners of the Company -Non-controlling interests         328.00         39,954.87         223.70         42,156.58           Other comprehensive income for the period attributable to: -Owners of the Company -Non-controlling interests         (7,433.45)         (4,588.50)         (3,260.00)         (13,874.66)           Other comprehensive income for the period attributable to: -Owners of the Company -Non-controlling interests         (7,433.45)         (4,588.50)         (3,269.00)         (13,874.66)           Other comprehensive income for the period attributable to: -Owners of the Company         (7,105.45)         35,366.37         (3,045.30)         228,201.72           Ano-controlling interests         Company         (7,105.45)         35,366.37         (3,045.30)         228,201.72           Earnings per equity share: (face value of Rs. 2 each) (not annualised) -for controlling interests         0.14         0.14         0.13         (0.13)         (0.11)           (1) Basic (in Rs.)         Controlling indiscontinued operations         -         16.36         0.22         17.70           (1) Basi			and the second se	We consider	2007 CA		
Profit for the period attributable to:         328.00         39,954.87         223.70         42,166.58           - Owners of the Company         328.00         39,954.87         223.70         42,166.58           - Non-controlling interests         120.00         515.10         1.00         286.40           Other comprehensive income for the period attributable to:         -         -         -         -           - Owners of the Company         (7,433.45)         (4,588.50)         (3,269.00)         (13,954.86           - Non-controlling interests         (84.50)         32.60         67.30         83.00           Total comprehensive income for the period attributable to:         -         -         -         -           - Owners of the Company         (7,105.45)         35,366.37         (3,045.30)         28,201.72           - Non-controlling interests         55.50         547.70         68.30         1,009.40           Earnings per equity share: (face value of Rs. 2 each) (not annualised)         -         0.14         0.14         0.13         0.13         0.11           - for continuing operations         0.14         0.13         0.13         0.13         0.11         0.11           (1) Basic (in Rs.)         -         16.36         0.22			(7,497.95)	(4,555.90)	(3,201.70)	(13,871.86)	
- Owners of the Company         328.00         39,954.87         223.70         42,156.58           - Non-controlling Interests         120.00         515.10         1.00         926.40           Other comprehensive income for the period attributable to:         -         -         -         -           - Owners of the Company         (7,433.45)         (4,588.50)         (3,269.00)         (13,954.66)           - Non-controlling interests         (64.50)         32.60         67.30         83.00           Total comprehensive income for the period attributable to:         -         -         -         -           - Owners of the Company         (7,105.45)         35,366.37         (3,045.30)         228,201.72           - Non-controlling interests         55.50         547.70         68.30         1,009.40           Earnings per equity share: (face value of Rs. 2 each) (not annualised)         -         6         6         1,009.40           - for continuing operations         0.14         0.14         0.013         0.011         1,009.40           (1) Basic (in Rs.)         0.14         0.14         0.013         0.011         1,009.40           (2) Diluted (in Rs.)         -         61.36         0.22         1,7.51           (1) Basic (in	xII	Total comprehensive income for the period (XI+XII)	(7,049.95)	35,914.07	(2,977.00)	29,211.12	
- Owners of the Company         328.00         39,954.87         223.70         42,156.58           - Non-controlling Interests         120.00         515.10         1.00         926.40           Other comprehensive income for the period attributable to:         -         -         -         -           - Owners of the Company         (7,433.45)         (4,588.50)         (3,269.00)         (13,954.66)           - Non-controlling interests         (64.50)         32.60         67.30         83.00           Total comprehensive income for the period attributable to:         -         -         -         -           - Owners of the Company         (7,105.45)         35,366.37         (3,045.30)         228,201.72           - Non-controlling interests         55.50         547.70         68.30         1,009.40           Earnings per equity share: (face value of Rs. 2 each) (not annualised)         -         6         6         1,009.40           - for continuing operations         0.14         0.14         0.013         0.011         1,009.40           (1) Basic (in Rs.)         0.14         0.14         0.013         0.011         1,009.40           (2) Diluted (in Rs.)         -         61.36         0.22         1,7.51           (1) Basic (in		Profit for the period attributable to:					
- Non-controlling interests       120.00       515.10       1.00       926.40         Other comprehensive income for the period attributable to:       7(33.45)       (4,588.50)       (3,269.00)       (13,954.86)         - Non-controlling interests       (64.50)       32.60       67.30       88.00         Total comprehensive income for the period attributable to:       (7,105.45)       35,366.37       (3,045.30)       28,201.72         - Owners of the Company       (7,105.45)       35,366.37       (3,045.30)       28,201.72         - Non-controlling interests       (7,105.45)       35,366.37       (3,045.30)       28,201.72         - Non-controlling operations       (1,09.40)       (1,09.40)       (1,09.40)       (1,09.40)         - for continuing operations       (1,013)       (0,111)       (1,013)       (0,111)       (1,013)       (0,111)         (2) Diluted (in Rs.)       (1,013)       (0,113)       (0,113)       (0,114)       (1,013) <t< td=""><td rowspan="4"></td><td></td><td>328.00</td><td>39,954,87</td><td>223.70</td><td>42,156,58</td></t<>			328.00	39,954,87	223.70	42,156,58	
Other comprehensive income for the period attributable to:         (7,433,45)         (4,588,50)         (3,269,00)         (13,954,86)           - Owners of the Company         (64,50)         32,60         67,30         83,00           Total comprehensive income for the period attributable to:         (64,50)         32,60         67,30         83,00           - Owners of the Company         (7,105,45)         35,366,37         (3,045,30)         28,201,72           - Owners of the Company         (7,105,45)         35,366,37         (3,045,30)         28,201,72           - Non-controlling interests         55,50         547,70         68,30         1,009,400           Earnings per equity share: (face value of Rs. 2 each) (not annualised)         -         61,4         0,14         (0,13)         (0,11)           - for continuing operations         0,14         0,14         (0,13)         (0,11)           (1) Basic (in Rs.)         0,13         0,13         0,13         (0,13)         (0,11)           - for continuing and discontinued operations         -         16,36         0,22         17,40           (1) Basic (in Rs.)         -         16,25         0,22         17,40           - for continuing and discontinued operations         -         16,25         0,09			and the second se	and the second se		24 (2007) 000-001	
- Owners of the Company       (7,433.45)       (4,585.50)       (3,269.00)       (13,954.86         - Non-controlling interests       (64.50)       32.60       67.30       88.00         Total comprehensive income for the period attributable to:       (7,105.45)       35,366.37       (3,045.30)       228,201.72         - Owners of the Company       (7,105.45)       35,366.37       (3,045.30)       228,201.72         - Non-controlling interests       55.50       547.70       68.30       1,009.40         Earnings per equity share: (face value of Rs. 2 each) (not annualised)       - for continuing operations       0.14       0.14       (0.13)       (0.11)         - for continuing operations       0.14       0.14       0.013       (0.11)       (0.11)         - for discontinued operations       0.14       0.14       0.013       (0.11)         - for discontinued operations       -       16.36       0.22       17.51         (1) Basic (in Rs.)       -       16.36       0.22       17.40         - for continuing and discontinued operations       -       16.25       0.22       17.40         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09 <td></td> <td></td> <td></td> <td></td> <td></td>							
- Non-controlling interests       (64.50)       32.60       67.30       88.00         Total comprehensive income for the period attributable to:       -       -       -       -         - Owners of the Company       (7,105.45)       35,366.37       (3,045.30)       228,201.72         - Non-controlling interests       55.50       547.70       68.30       1,009.40         Earnings per equity share: (face value of Rs. 2 each) (not annualised)       -       -       -       -         - for continuing operations       0.14       0.14       (0.13)       (0.11)         (1) Basic (in Rs.)       0.13       0.13       (0.13)       (0.11)         - for discontinued operations       -       -       -       -         (1) Basic (in Rs.)       -       16.36       0.22       17.51         (2) Diluted (in Rs.)       -       16.25       0.22       17.40         - for continuing and discontinued operations       -       -       -       -         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       -       -       16.36       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29			(7,433.45)	(4,588.50)	· (3,269.00)	(13,954.86)	
- Owners of the Company       (7,105.45)       35,366.37       (3,045.30)       28,201.72         - Non-controlling interests       55.50       547.70       68.30       1,009.40         Earnings per equity share: (face value of Rs. 2 each) (not annualised)       -       -       68.30       1,009.40         - for continuing operations       0.14       0.14       (0.13)       (0.11)         (1) Basic (in Rs.)       0.13       0.13       (0.13)       (0.11)         - for discontinued operations       0.14       0.14       (0.13)       (0.11)         (1) Basic (in Rs.)       0.13       0.13       (0.12)       10.11         (2) Diluted (in Rs.)       -       16.36       0.22       17.51         (2) Diluted (in Rs.)       -       16.25       0.22       17.40         - for continuing and discontinued operations       -       16.25       0.22       17.40         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29		- Non-controlling interests	(64.50)	32.60		83.00	
- Owners of the Company       (7,105.45)       35,366.37       (3,045.30)       28,201.72         - Non-controlling interests       55.50       547.70       68.30       1,009.40         Earnings per equity share: (face value of Rs. 2 each) (not annualised)       -       -       68.30       1,009.40         - for continuing operations       0.14       0.14       (0.13)       (0.11)         (1) Basic (in Rs.)       0.13       0.13       (0.13)       (0.11)         - for discontinued operations       0.14       0.14       (0.13)       (0.11)         (1) Basic (in Rs.)       0.13       0.13       (0.12)       10.11         (2) Diluted (in Rs.)       -       16.36       0.22       17.51         (2) Diluted (in Rs.)       -       16.25       0.22       17.40         - for continuing and discontinued operations       -       16.25       0.22       17.40         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29		the state of the state and the state of the state of the state					
Earnings per equity share: (face value of Rs. 2 each) (not annualised)         0.14         0.14         0.13         0.011           - for continuing operations         0.14         0.14         0.013         0.011           (1) Basic (in Rs.)         0.13         0.13         0.013         0.011           - for discontinued operations         0.13         0.13         0.011           (1) Basic (in Rs.)         -         16.36         0.22         17.51           (2) Diluted (in Rs.)         -         16.25         0.22         17.40           - for continuing and discontinued operations         -         16.25         0.22         17.40           (1) Basic (in Rs.)         0.14         16.50         0.09         17.40           (2) Diluted (in Rs.)         0.13         16.38         0.09         17.29		- Owners of the Company	(7,105.45)	35,366.37	(3,045.30)	28,201.72	
- for continuing operations         0.14         0.14         0.13         0.11           (1) Basic (in Rs.)         0.13         0.13         0.13         (0.11)           (2) Diluted (in Rs.)         0.13         0.13         (0.13)         (0.11)           - for discontinued operations         -         16.36         0.22         17.51           (2) Diluted (in Rs.)         -         16.25         0.22         17.40           - for continuing and discontinued operations         -         16.50         0.09         17.40           (1) Basic (in Rs.)         0.14         16.50         0.09         17.40           (2) Diluted (in Rs.)         0.13         16.38         0.09         17.29		- Non-controlling interests	55.50	547.70	68.30	1,009.40	
(1) Basic (in Rs.)       0.14       0.14       (0.13)       (0.11)         (2) Diluted (in Rs.)       0.13       0.13       (0.13)       (0.11)         - for discontinued operations       -       16.36       0.22       17.51         (1) Basic (in Rs.)       -       16.36       0.22       17.51         (2) Diluted (in Rs.)       -       16.25       0.22       17.40         - for continuing and discontinued operations       -       16.50       0.09       17.40         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29							
(2) Diluted (in Rs.)       0.13       0.13       (0.1)         - for discontinued operations       -       16.36       0.22       17.51         (1) Basic (in Rs.)       -       16.36       0.22       17.51         (2) Diluted (in Rs.)       -       16.25       0.22       17.40         - for continuing and discontinued operations       -       16.50       0.09       17.40         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29			0.44	0.14	(0.12)	(0.11)	
- for discontinued operations         -         16.36         0.22         17.51           (1) Basic (in Rs.)         -         16.36         0.22         17.51           (2) Diluted (in Rs.)         -         16.25         0.22         17.40           - for continuing and discontinued operations         -         16.50         0.09         17.40           (1) Basic (in Rs.)         0.14         16.50         0.09         17.40           (2) Diluted (in Rs.)         0.13         16.38         0.09         17.29						10	
(1) Basic (in Rs.)       -       16.36       0.22       17.51         (2) Diluted (in Rs.)       -       16.25       0.22       17.40         - for continuing and discontinued operations       -       16.50       0.09       17.40         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29			0.13	0.13	(0.13)	(0.11)	
(2) Diluted (in Rs.)       -       16.25       0.22       17.40         - for continuing and discontinued operations       -       -       -       10.25       10.25       10.25         (1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29				16.36	0.22	17.51	
- for continuing and discontinued operations         0.14         16.50         0.09         17.40           (1) Basic ( in Rs.)         0.13         16.38         0.09         17.29	1	Constant of the second s		A MAR SHOW OF		17.40	
(1) Basic (in Rs.)       0.14       16.50       0.09       17.40         (2) Diluted (in Rs.)       0.13       16.38       0.09       17.29				1 (Arrest 1997)		411111-1335	
(2) Diluted (in Rs.) 0.13 16.38 0.09 17.29			0.14	16.50	0.09	17.40	
See accompanying notes to the financial results		(2) Diluted (in Rs.)				17.29	
		See accompanying notes to the financial results	(	and the second		X	

w



# Sequent

Proven Ability in Life Sciences

#### SEQUENT SCIENTIFIC LIMITED

Votes

1. The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 9 August 2018. 2. The Company has only one reportable segment viz, Pharmaceuticals, Accordingly, no separate disclosure of segment information has been made,

3. Information on Standalone Results:	tion on Standalone Results: (Rs in Lakhs)			
Particulars	3 months encled 30-Jun-2018	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year encled 31-Mar-2018
	UNAUDITED	AUDITED (Refer note 11)	UNAUDITED	AUDITED
Revenue from continuing operations	2,628.50	2,679.50	2,728,20	10,723.60
Profit/ (Loss) before tax from continuing operations	261.90	(170.40)	(273.50)	66.30
Profit/ (Loss) after tax from continuing operations	261.90	(404,92)	(273.50)	(220.37)
Profit/ (Loss) after tax from discontinued operations		39,516,43	826.70	40,861.10
Total comprehensive income	(7.459.00)	33,978,45	(2.675.70)	26,408,03

4a, Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018 ('Order'), with effect from the Appointment Date I.a. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited ('Solara).

Pursuant to the above, Sequent Penems Private Limited has ceased to be the subsidiary of the Company.

In line with the approved Scheme, the comparative information in these results for the quarter ended 30 June 2017 have been revised from the published financial results for that quarter to exclude the results of Human API business and Sequent Penems Private Limited which had revenue of Rs. 8,470.00 lakhs and expenses of Rs. 7,650,51 lakhs.

4b, During the previous year ended 31 March 2018, the Company completed the divestment of woman healthcare business (discontinued operations).

The results relating to discontinued business are as follows:

Particulars	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	AUDITED (Refer note 11)	UNAUDITED	AUDITED
Total income		10,225.92	18,575.74
Total expenses		10,059,69	17,521.04
Profit/ (Loss) before exceptional items and tax		166.23	1,054.70
Exceptional items			
Profit/ (Loss) before tax		166.23	1,054.70
Gain on disposal of assets/settlement of liabilities attributable to the discontinuing operations	39,264.00	•	41,009.50
Tax Expense of discontinued operations	(362.73)		
Profit/ (Loss) for the period	39,626.73	166.23	42,064.20

5. Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duly up to 30 June 2017. Accordingly, revenue from operations for the quarter ended 30 June 2018 are not comparable with those of the previous periods presented.

Particulars	ended 31-Mar-2018 AUDITED (Refer note 11) 1 16.10	Previous year ended 31-Mar-2018	
		AUDITED	
Write off of ineligible GST credits	1 16.10	116.10	
Goodwill impairment	790.00	790.00	
Contingent consideration reversal	(931.26)	(931.26)	
liability towards pre-acquisition emptoyee claims	175,56	175.56	
Total	150,40	150.40	

7. With effect from 01 April 2018, the Company, through its step down subsidiary Alivira Animal Health Limited, Ireland, has acquired 100% stake in Bremer Pharma GMBH (Bremer). The Company is in process of completing the Purchase Price Allocations of this acquisition and the business combination has been accounted for based on provisional amounts as permitted under the Indian Accounting Standard 103 "Business Combinations", The results for the quarter ended 30 June 2018 includes Revenue from operations Rs, 1,283,01 lakhs and Loss after tax Rs, 45,29 lakhs relating to Bremer.

8. During the quarter, the Company has revised the useful life of certain acquired intangibles a 2014 from 5 years, to 20 years, Had the useful life been 5 years, the profit for the quarter ended 30 June 2018 would have reduced by Rs. 167.55 lakhs (net of deferred tax Rs. 54.09 lakhs).

9. 'Ind AS 115 - Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018, Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.

10. The Company has assessed the impact of amendment to Appendix B to 'Ind AS 21- The Effects of Changes in Foreign Exchange Rates', effective from 01 April 2018, in respect of advances received / paid in foreign currency, and noted no material impact.

11. The above results includes the results for the quarter ended 31 March 2018, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date ligures up to the third quarter of the previous financial year.

12. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited ann Manish Gunta Managing Director

TENT

Place : Mumbai Date : 9 August 2018

# Deloitte Haskins & Sells

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru – 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

# INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

## TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

 We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company"), for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS** Chartered Accountants (Firm's Registration No. 008072S)

Sathya P. Koushik Partner Membership No. 206920)

Mumbai, August 09, 2018 SPK/JKS/2018

### Sequent Proven Ability in Life Sciences

SEQUENT SCIENTIFIC LIMITED

### STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

	Particulars	3 months ended 30-Jun-2018	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in previous year 30-Jun-2017	Previous year ended 31-Mar-2018
		Unaudited	Audited (Refer note 10)	Unaudited	Audited
1	Revenue from operations (Refer note 3)	2.628.50	2,679.50	2,728.20	10,723.60
Ш	Other income	435.60	509.40	443.90	2,426.90
III	Total income (I+II)	3,064.10	3,188.90	3,172.10	13,150.50
IV	Expenses				
	(a) Cost of materials consumed	916.10	1,102.20	581.00	3,065.70
	(b) Purchases of stock-in-trade	1,026.60	948.10	1,262.00	4,914.30
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(160.80)	(35.10)	0.30	(42.20
	(d) Excise duty on sale of goods		-	122.90	122.90
	(e) Conversion and processing charges	398.00	417.88	238.20	1,175.60
	(f) Employee benefits expense	157.50	182.50	363.60	1,185.00
	(g) Finance costs		8.10	17.50	39.20
		1.30	A REAL PROPERTY AND A REAL	Construction of the second second	
	(h) Depreciation and amortisation expense	87.70	114.40	75.50	366.70
	(i) Other expenses	375.80	505.12	784.60	2,140.90
	Total expenses (IV)	2,802.20	3,243.20	3,445.60	12,968.10
v	Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	261.90	(54.30)	(273.50)	182.40
VI	Exceptional items (gain) / loss (Refer note 7)	-	116.10		116.10
/11	Profit/(loss) from continuing operations before tax (V-VI)	261.90	(170.40)	(273.50)	66.30
/111	Tax expense				
	(a) Current tax	55.60	(48.28)		3.87
	(b) MAT credit entitlement	(55.60)	(3.87)	-	(3.87
	(c) MAT credit entitlement written off	-	286.67	-	286.67
	Total tax expenses (VIII)	-	234.52	•	286.67
x	Profit/(loss) from continuing operations after tax (VII-VIII)	261.90	(404.92)	(273.50)	(220.37
х	Profit/(loss) from discontinued operations	-		826.70	1,707.40
	Gain on demerger of Human API business	-	39,153.70	-	39,153.70
	Tax expense of discontinued operations				
	(a) Current tax	-		-	362.73
	(b) MAT credit entitlement		(362.73)		(362.73
	Profit/(loss) from discontinued operations after tax (X) (Refer note 9)	-	39,516.43	826.70	40,861.10
XI	Profit/(loss) for the period (IX+X)	261.90	39,111.51	553.20	40,640.73
KII	Other comprehensive income				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurements of defined benefits plans	(9.00)	(34.06)	1.90	(37.30
	(b) Fair value gain / (loss) from investment in equity instruments (net)	(7,711.90)	(5,099.00)	(3,230.80)	(14,195.40
	Total other comprehensive income for the period (XII)	(7,720.90)	(5,133.06)	(3,228.90)	(14,232.70
cIII	Total comprehensive income for the period (XI+XII)	(7,459.00)	33,978.45	(2,675.70)	26,408.03
W	Earnings per equity share: (Face value of Rs. 2 each) (not-annualised)				
	- for continuing operations		10.471	10.11	10.00
	(1) Basic ( in Rs.)	0.11	(0.17)	(0.11)	(0.09
	(2) Diluted (in Rs.)	0.11	(0.17)	(0.11)	(0.09
	- for discontinued operations				
	(1) Basic ( in Rs.)	-	16.31	0.34	16.86
	(2) Diluted (in Rs.)	-	16.20	• 0.34	16.75
	- for continuing and discontinued operations				
	(1) Basic (in Rs.)	0.11	16.14	0.23	16.77
	(2) Diluted (in Rs.)	0.11	16.03	0.23	16.66



w

## Sequent

#### SEQUENT SCIENTIFIC LIMITED

#### Notes:

1 The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 09 August 2018.

- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty upto 30 June 2017. Accordingly, revenue from operations for the quarter ended 30 June 2018 are not comparable with those of the previous periods presented.
- 4 During the quarter, the Company, through its step down subsidiary Alivira Animal Health Limited, Ireland, has acquired 100% stake in Bremer Pharma GMBH.
- 5 'Ind AS 115- Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- 6 The Company has assessed the impact of amendment to Appendix B to 'Ind AS 21- The Effects of Changes in Foreign Exchange Rates', effective from 01 April 2018, in respect of advances received / paid in foreign currency, and noted no material impact.
- 7 Exceptional items for the quarter and year ended 31 March 2018 comprises write-off of ineligible GST credits.
- 8 Tax expenses has been accrued during the current quarter based on estimated Minimum Alternate Tax applicable to the entity and for previous periods, tax expenses are split between continuing and discontinued operations based on book profits from the respective operations.
- 9 Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018, with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited. In line with the approved Scheme, the comparative information in these results for the quarter ended 30 June 2017 have been revised from the published financial results for that quarter to exclude the result of the Human API business which had a revenue of Rs. 8,461.60 lakhs and expenses of Rs. 7,634.90 lakhs.

Particulars	Preceding 3 months ended 31-Mar-2018	months ended previous year	Previous year ended 31-Mar-2018 Audited
Total income		8,461.60	16,795.60
Total expenses	-	7,634.90	15,088.20
Profit/(loss) before exceptional items and tax		826.70	1,707.40
Exceptional items	-	-	-
Profit/(loss) before tax		826.70	1,707.40
Gain on demerger of Human API business	39,153.70	-	39,153.70
Tax expense	(362.73)	-	
Profit/(loss) for the period	39,516.43	826.70	40,861.10

10 The above results includes the results for the quarter ended 31 March 2018, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.

11 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited NT a Manish Gupta **Managing Director** 4

Place : Mumbai Date : 09 August 2018

w